Titel
Accueil
Navigation principale
Contenu
Recherche
Aide
Fonte
Standard
Gras
Identifiant
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Accueil
Plus de données
Partenaires
Aide
Mentions légales
D
F
E
La recherche est en cours.
Interrompre la recherche
Recherche de projets
Projet actuel
Projets récents
Graphiques
Identifiant
Titel
Titel
Unité de recherche
SEFRI
Numéro de projet
23.00160
Titre du projet
Fighting childhood obesity to stay healthy all over the life
Données de base
Textes
Participants
Titel
Textes relatifs à ce projet
Allemand
Français
Italien
Anglais
Résumé des résultats (Abstract)
-
-
-
Textes saisis
Catégorie
Texte
Résumé des résultats (Abstract)
(Anglais)
Obesity rates in late teens has increased in Europe from 6% in 1980 to 32%, with long-lasting effects on the prevalence of severe obesity, diabetesand cardiovascular disease, premature death and disability. Efficiently fighting adult obesity is difficult but prevention and treatment of obesity have proven to work better at young ages. OBELISK goal is to cut the roots of the pandemic of obesity in Europe targeting children first. OBELISK is focused on elucidating, Predicting, Preventing obesity and bringing Precision medicine for children with obesity. OBELISK medicine is also Participative (4P), leveraging the potential of social innovation through engagement with families, scientific and medical communities, daycare, schools, municipalities, industries to achieve success. OBELISK objectives are: 1/ to bring breakthroughs in the molecular mechanisms by which causative factors interact to drive (or prevent) the transition from normal weight to obesity during childhood and to develop and exploit for prevention and treatment early predictive proprietary tools; 2/ to identify at least three novel childhood obesity genes with the prospect of identifying additional drug targets; 3/ to demonstrate the utility of targeted approaches to prevent childhood obesity; 4/ to bring breakthroughs in childhood obesity treatment including an innovative trial of a promising existing drug (GLP1R agonist) to reverse obesity in teens with predisposing genetic mutations; 5/ to exploit the project results and disseminate best practices to prevent and treat childhood obesity, implementing education programs, and translating OBELISK clinical results into guidelines and proposals for policy makers to change obesity care; 6/ to facilitate the networking and exchanges with other actions and projects in order to optimize knowledge and joint activities. OBELISK targeted approach should contribute to prevent 30% of cases of childhood obesity, helping them to stay healthy all over their life.
SEFRI
- Einsteinstrasse 2 - 3003 Berne -
Mentions légales